Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review
- 1 October 2014
- journal article
- review article
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 44 (2) , 175-185
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic ReviewArthritis Care & Research, 2013
- Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysisJournal of Zhejiang University-SCIENCE B, 2012
- Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)Lupus, 2011
- Off-label use of rituximab in systemic lupus erythematosus: a systematic reviewClinical Rheumatology, 2010
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapiesBest Practice & Research Clinical Rheumatology, 2009
- Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide‐resistant proliferative lupus nephritisArthritis & Rheumatism, 2007
- Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot studyArthritis Research & Therapy, 2006
- Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down‐regulation of the T cell costimulatory molecule CD40 ligand: An open‐label trialArthritis & Rheumatism, 2005
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996